Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 09 March 2015 | By Michael Mezher
A generic drug maker has launched its copy of Gilead Sciences' hepatitis C drug Sovaldi—which costs $84,000 in the US—which it will sell in Bangladesh for just $900 under the brand name Hopetavir, Bloomberg reports.
Incepta Pharmaceuticals, a Bangladeshi company, is selling a 12-week course of a generic version of Gilead Sciences' Sovaldi for $900—almost 99% less than Gilead’s US price for the drugs—and has its eye on other markets where Sovaldi is not patented.
Sovaldi made headlines in 2014 for both its significant improvement over previous treatments for hepatitis C (HCV) as well as its price tag. At its launch, Sovaldi was priced at $84,000 in the US, a figure that drew the attention of US lawmakers and payer groups. Prices for Sovaldi vary by market; in Germany and the UK the drug launched at the equivalent of $66,000 and $57,000, respectively.
In September 2014, Gilead said it would license Sovaldi to multiple generic manufacturers in India. The licensing agreement would allow the generic manufacturers to market Sovaldi in India and 90 other low- and middle-income countries. Gilead has said it will price Sovaldi at $900 in India, though licensed generics could sell for less.
Some have criticized Gilead’s licensing practices, which leave out a number of countries where HCV is prevalent, including Brazil and Thailand.
Bloomberg is reporting that the World Health Organization (WHO) is considering reviewing Hopetavir under its prequalification program, which could make the drug available in countries where Sovaldi lacks patent protection, and to humanitarian groups such as Médecins Sans Frontières (MSF).
Abdul Muktadir, managing director at Incepta, told Bloomberg his company “should be able to launch [Hopetavir] wherever it is required … in Africa, and some of the Southeast Asian countries.” He also said that the drug will probably not be a big profit source for the company, and expects prices to come down over time.
Bangladesh is a member of the World Trade Organization (WTO), where it is classified as a least-developed country (LDC).
WTO members are required to abide by the requirements in the agreement on Trade-Related Aspects of Intellectual Property (TRIPS), which include recognition of patents for pharmaceutical products. However, LDCs were given longer to comply with the pharmaceutical provisions in TRIPS. Presently, the TRIPS Council is giving LDCs until 1 July 2021 to meet their obligations to provide intellectual property protection for pharmaceuticals, though LCD members are looking to extend the transition period for more time.
Bloomberg
Tags: Gilead, Sovaldi, Sofosbuvir, Bangladesh, Hopetavir
Regulatory Focus newsletters
All the biggest regulatory news and happenings.